Literature DB >> 10425110

Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.

T Suzuki1, T Ando, K Tsuchiya, N Fukazawa, A Saito, Y Mariko, T Yamashita, O Nakanishi.   

Abstract

Newly synthesized benzamide derivatives were evaluated for their inhibitory activity against histone deacetylase. The structure of these derivatives was unrelated to the known inhibitors, and IC(50) values of the active compounds were in the range of 2-50 microM. Structure-activity relationship on the benzanilide moiety showed that the 2'-substituent, an amino or hydroxy group, was indispensable for inhibitory activity. Although the electronic influence of the substituent in the anilide moiety showed only a small effect on inhibitory activity, the steric factor in the anilide moiety, especially at positions 3'and 4', played an important role in interaction with the enzyme. Among these benzamide derivatives, MS-275 (1), which showed significant antitumor activity in vivo, has been selected for further investigation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10425110     DOI: 10.1021/jm980565u

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  48 in total

1.  The effect of MS-275 on CYP450 isoforms activity in rats by cocktail method.

Authors:  Qing Wu; Qingwei Zhang; Congcong Wen; Lufeng Hu; Xianqin Wang; Guanyang Lin
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

Review 2.  Recent advances in the development of polyamine analogues as antitumor agents.

Authors:  Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

3.  Use of polyamine derivatives as selective histone deacetylase inhibitors.

Authors:  Patrick M Woster
Journal:  Methods Mol Biol       Date:  2011

4.  Developing consensus 3D-QSAR and pharmacophore models for several beta-secretase, farnesyl transferase and histone deacetylase inhibitors.

Authors:  Hsin-Yuan Wei; Guan-Ju Chen; Chih-Lun Chen; Thy-Hou Lin
Journal:  J Mol Model       Date:  2011-05-12       Impact factor: 1.810

Review 5.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

6.  Entinostat: a promising treatment option for patients with advanced breast cancer.

Authors:  Roisin M Connolly; Michelle A Rudek; Richard Piekarz
Journal:  Future Oncol       Date:  2017-03-09       Impact factor: 3.404

7.  Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

Authors:  Milin R Acharya; Judith E Karp; Edward A Sausville; Kyunghwa Hwang; Qin Ryan; Ivana Gojo; Jurgen Venitz; William D Figg; Alex Sparreboom
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

8.  Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors.

Authors:  Sheeba Varghese; Thulani Senanayake; Tracey Murray-Stewart; Kim Doering; Alison Fraser; Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2008-03-19       Impact factor: 7.446

9.  Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer.

Authors:  Noriyuki Takai; Hisashi Narahara
Journal:  Obstet Gynecol Int       Date:  2010-02-04

10.  Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism.

Authors:  Sridar V Chittur; Niquiche Sangster-Guity; Paulette J McCormick
Journal:  BMC Genomics       Date:  2008-10-29       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.